Tackling the non-linearizeable dose-response relationship in clotting time assays of heparin

L O Zwillenberg1, G Bösiger

  • 1Biologisches Forschungslaboratorium Dres. Zwillenberg, Bern, Switzerland.

Heparin sodium was assayed by turbidimetric measurement of the clotting time of bovine citrate plasma with thromboplastin, between the moment of recalcification and the moment of maximal speed of polymerization of the fibrinogen monomer, as marked by the turning-point of the trace of the turbidimetric record. Most assays were practiced in the range of 0.2-2.0 units per test volume. The lower end of the range could be extended by decreasing the thromboplastin dose, the higher end by increasing this dose. The dose-response relationship for heparin sodium, i.e. between the nominal heparin activity x and the clotting time y, was non-linear in such a way that no uniform mathematical transformation could provide a valid linearization over the whole range. A non-linear regression in the form of a cubic fit, applied to the data pairs (x, y) of both standard and test sample, proved to be satisfactory. The two non-linear regression curves were compared at varying levels of x by computing the quotient of nominal and actual activity for equal clotting times, and by computing the quotient of the slopes (tangents) of the curves for these times. The percentual deviation of the test sample potency from the standard's potency as obtained from the former quotient was termed Za, and the deviation as computed from the latter quotient was termed Ztg, Za and Ztg as functions of x were plotted and were found to intersect invariably at critical points of Za(x) within the range of the experiment. This seems to be a theorem.(ABSTRACT TRUNCATED AT 250 WORDS)

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect01:28

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...